TaiMed Biologics Inc. (TPEX:4147)

Taiwan · Delayed Price · Currency is TWD

55.00

-0.10 (-0.18%)

Nov 6, 2026, 1:30 PM CST

Market Cap	15.03B -20.4%
Revenue (ttm)	619.49M +3.6%
Net Income	-138.90M
EPS	-0.51
Shares Out	273.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,673,235
Open	50.30
Previous Close	55.10
Day's Range	49.65 - 55.50
52-Week Range	47.00 - 75.40
Beta	-0.01
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About TaiMed Biologics

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antib... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2007

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 4147

Full Company Profile

Financial Performance

In 2025, TaiMed Biologics's revenue was 611.35 million, an increase of 0.19% compared to the previous year's 610.16 million. Losses were -167.78 million, -16.87% less than in 2024.

Financial Statements